|Bid||4.0700 x 1000|
|Ask||4.0800 x 1400|
|Day's Range||3.8200 - 4.1800|
|52 Week Range||0.5500 - 6.0700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
At this time, I would like to turn the call over to Mei Kuo, director of communications and investor relations. Joining me today are; Jim Mish, our chief executive officer; Mike Zercher, our president and chief operating officer; and John Franzino, our chief financial officer.
22nd Century (XXII) delivered earnings and revenue surprises of 0.00% and -6.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
With so much hype around cannabis legalization at the state, and potentially federal, level, it can be easy to lose track of the debate involving cigarette smoking and nicotine addiction. Now comes word that the Biden administration is considering a proposal from the U.S. Food and Drug Administration (FDA) to reduce nicotine levels in all cigarettes sold in the U.S. to minimally or non-addictive levels. For 22nd Century, in particular, this could be the moonshot it's been waiting for.